RLAY Relay Therapeutics

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024

CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 6, 2024.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit or .

Contact:

Megan Goulart

617-545-5526

Media:

Dan Budwick

1AB

973-271-6085



EN
30/10/2024

Underlying

RLAYRelay Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Relay Therapeutics

 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Co...

Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of RLY-2608 + fulvestrant in 2025 Approximately $840 million in cash, cash equivalents and investments at end of Q3 2024, expected to fund operations into second half of 2027 CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the dru...

4h / 25m 1 EN
 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics to Announce Third Quarter 2024 Financial Results an...

Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 6, 2024. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company t...

October 30, 2024 1 EN
 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics Announces Pricing of Public Offering of Common Stoc...

Relay Therapeutics Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten public offering of 28,571,429 shares of its common stock at a public offering price of $7.00 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional 4,285,714 shares of its common stock. The gross pr...

September 11, 2024 1 EN
 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics Announces Proposed Public Offering of Common Stock

Relay Therapeutics Announces Proposed Public Offering of Common Stock CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering of $200 million of shares of its common stock. Relay Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public off...

September 9, 2024 1 EN
 PRESS RELEASE
Free
RLAY Relay Therapeut...

Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demons...

Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse events & only 1 patient experienced Grade 3 hyperglycemia Data support planned initiation of 2L pivotal study in 2025 Triplet combination with ribociclib expec...

September 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch